Rockefeller Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $63M | Buy |
373,548
+91,451
| +32% | +$13.6M | 0.1% | 193 |
|
|
2026
Q1 | $37.2M | Buy |
282,097
+777
| +0.3% | +$103K | 0.07% | 280 |
|
|
2025
Q4 | $39.9M | Buy |
281,320
+87,372
| +45% | +$12.7M | 0.07% | 261 |
|
|
2025
Q3 | $27.2M | Buy |
193,948
+80,719
| +71% | +$10.9M | 0.05% | 331 |
|
|
2025
Q2 | $14.2M | Buy |
113,229
+91,630
| +424% | +$10.5M | 0.03% | 494 |
|
|
2025
Q1 | $2.39M | Buy |
21,599
+1,729
| +9% | +$219K | 0.01% | 968 |
|
|
2024
Q4 | $2.71M | Buy |
19,870
+549
| +3% | +$67.9K | 0.01% | 906 |
|
|
2024
Q3 | $2.23M | Buy |
19,321
+44
| +0.2% | +$6.03K | 0.01% | 957 |
|
|
2024
Q2 | $2.65M | Buy |
+19,277
| New | +$2.64M | 0.01% | 882 |
|
|
2023
Q3 | – | Sell |
-6,945
| Closed | -$655K | – | 1710 |
|
|
2023
Q2 | $655K | Buy |
6,945
+219
| +3% | +$21.4K | ﹤0.01% | 1240 |
|
|
2023
Q1 | $680K | Sell |
6,726
-295
| -4% | -$30.7K | ﹤0.01% | 1220 |
|
|
2022
Q4 | $838K | Sell |
7,021
-59
| -0.8% | -$6.91K | ﹤0.01% | 1079 |
|
|
2022
Q3 | $751K | Sell |
7,080
-149
| -2% | -$15.1K | ﹤0.01% | 1113 |
|
|
2022
Q2 | $703K | Sell |
7,229
-5,313
| -42% | -$490K | ﹤0.01% | 1123 |
|
|
2022
Q1 | $1.18M | Sell |
12,542
-199
| -2% | -$16.9K | 0.01% | 1000 |
|
|
2021
Q4 | $1.08M | Sell |
12,741
-8,680
| -41% | -$798K | 0.01% | 1028 |
|
|
2021
Q3 | $2.05M | Sell |
21,421
-599,300
| -97% | -$56.6M | 0.01% | 738 |
|
|
2021
Q2 | $60.4M | Sell |
620,721
-2,176
| -0.3% | -$209K | 0.34% | 63 |
|
|
2021
Q1 | $60.6M | Buy |
622,897
+16,005
| +3% | +$1.68M | 0.41% | 49 |
|
|
2020
Q4 | $58.2M | Buy |
606,892
+273,732
| +82% | +$26.4M | 0.44% | 45 |
|
|
2020
Q3 | $32M | Buy |
333,160
+259
| +0.1% | +$30K | 0.3% | 82 |
|
|
2020
Q2 | $40.6M | Buy |
332,901
+20,607
| +7% | +$2.28M | 0.43% | 49 |
|
|
2020
Q1 | $27M | Sell |
312,294
-10,161
| -3% | -$994K | 0.35% | 58 |
|
|
2019
Q4 | $34.7M | Sell |
322,455
-28,925
| -8% | -$3.03M | 0.43% | 48 |
|
|
2019
Q3 | $31.7M | Sell |
351,380
-13,391
| -4% | -$1.25M | 0.43% | 52 |
|
|
2019
Q2 | $30.8M | Buy |
364,771
+139,794
| +62% | +$11.5M | 0.43% | 56 |
|
|
2019
Q1 | $19.8M | Buy |
224,977
+221,302
| +6,022% | +$18.5M | 0.28% | 81 |
|
|
2018
Q4 | $262K | Hold |
3,675
| – | – | ﹤0.01% | 384 |
|
|
2018
Q3 | $452K | Hold |
3,675
| – | – | 0.01% | 290 |
|
|
2018
Q2 | $361K | Hold |
3,675
| – | – | 0.01% | 295 |
|
|
2018
Q1 | $305K | Buy |
+3,675
| New | +$310K | 0.01% | 302 |
|
Other funds holding NBIX
Rockefeller Capital Management's NBIX Position: Q2 2026 in Review
Rockefeller Capital Management increased its Neurocrine Biosciences (NBIX) stake by 32% in Q2 2026, buying an estimated $13.6M and bringing the position to 373,548 shares worth $63M. The position accounts for 0.1% of the portfolio, ranked #193.
Rockefeller Capital Management first reported a position in NBIX in Q1 2018 and has held it in 31 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Rockefeller Capital Management held 373,548 shares of Neurocrine Biosciences worth $63M as of Q2 2026.
- Rockefeller Capital Management bought 91,451 Neurocrine Biosciences shares in Q2 2026, an estimated $13.6M.
- Neurocrine Biosciences made up 0.1% of Rockefeller Capital Management's portfolio in Q2 2026, its #193 holding.
- Rockefeller Capital Management first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 31 quarters since.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.